PT-141 (Bremelanotide): From Research Peptide to Approved Medicine
PT-141 is a melanocortin-receptor research peptide that completed Phase-3 trials and reached FDA approval as bremelanotide in 2019. The melanocortin system, and the pipeline arc it illustrates.